Published in J Am Soc Nephrol on June 01, 2003
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int (2014) 3.40
Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol (2012) 1.98
Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol (2011) 1.83
A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant (2009) 1.75
Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol (2008) 1.35
The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int (2012) 1.31
Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol (2009) 1.29
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int (2015) 1.04
Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011) (2012) 1.01
Association of proteinuria with various clinical findings and morphologic variables of oxford classification in immunoglobulin a nephropathy patients. Int J Prev Med (2013) 0.98
Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol (2013) 0.96
The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int (2012) 0.95
Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis (2014) 0.92
Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin Dev Immunol (2011) 0.92
Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol (2013) 0.90
Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol (2011) 0.89
Henoch-Schönlein nephritis associated with streptococcal infection and persistent hypocomplementemia: a case report. J Med Case Rep (2010) 0.88
Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol (2008) 0.85
Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function. Clin Exp Nephrol (2011) 0.84
Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant (2010) 0.83
Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol (2011) 0.80
Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int (2006) 0.80
Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. Exp Ther Med (2013) 0.79
IgA nephropathy: what's new? Pediatr Nephrol (2007) 0.78
Glomerular diseases: emerging tests and therapies for IgA nephropathy. Clin J Am Soc Nephrol (2013) 0.78
Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. J Am Soc Nephrol (2016) 0.78
Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy? Nat Rev Nephrol (2010) 0.78
The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy. Clin Exp Nephrol (2015) 0.77
Continental variations in IgA nephropathy among Asians. Clin Nephrol (2008) 0.77
High-dose intravenous immunoglobulin pulse therapy in patients with progressive immunoglobulin A nephropathy: a long-term follow-up. Clin Exp Immunol (2006) 0.76
Following specific podocyte injury captopril protects against progressive long term renal damage. F1000Res (2015) 0.75
Use of low-dose sulodexide in IgA nephropathy patients on renin-angiotensin system blockades. Kidney Res Clin Pract (2012) 0.75
Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up. Clin Exp Immunol (2015) 0.75
Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial. Korean J Intern Med (2016) 0.75
Renin-Angiotensin system inhibitors reduce serum asymmetric dimethylarginine levels and oxidative stress in normotensive patients with chronic kidney disease. Nephron Extra (2014) 0.75
Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial. Trials (2014) 0.75
Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy? Clin Exp Immunol (2016) 0.75
Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria. Pediatr Nephrol (2005) 0.75
Outcome results in children with IgA nephropathy: a single center experience. Int J Nephrol Renovasc Dis (2012) 0.75
Comparison of immunosuppressive therapies for IgA nephropathy after tonsillectomy: three-course versus one-course steroid pulse combined with mizoribine. Int Urol Nephrol (2015) 0.75
Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clin Proteomics (2016) 0.75
Mesangial proliferative glomerulonephritis with aldosterone-producing adenoma. Clin Exp Nephrol (2007) 0.75
IgA nephropathy with presentation of nephrotic syndrome at onset in children. Pediatr Nephrol (2016) 0.75
Long-term outcome of childhood IgA nephropathy with minimal proteinuria. Pediatr Nephrol (2015) 0.75
Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents. Pediatr Nephrol (2017) 0.75
Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol (2006) 0.75
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care (2008) 4.20
Acute interstitial nephritis. Kidney Int (2010) 3.39
Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int (2002) 2.35
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) (2012) 2.03
AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol (2011) 1.40
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis (2003) 1.26
Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens (2006) 1.25
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2009) 1.21
Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol (2002) 1.16
Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol (2006) 1.08
Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int (2005) 1.07
Long-term renal survival in malignant hypertension. Nephrol Dial Transplant (2010) 1.05
Renal damage associated with proteinuria. Kidney Int Suppl (2002) 0.96
A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. Addict Behav (2011) 0.93
Haematuria: the forgotten CKD factor? Nephrol Dial Transplant (2012) 0.91
Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant (2012) 0.83
Unilateral pleural effusions associated with stenoses of left brachiocephalic veins in haemodialysis patients. Nephrol Dial Transplant (2005) 0.81
Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology (Carlton) (2014) 0.80
[Complex visual hallucinations induced by voriconazole]. Med Clin (Barc) (2009) 0.79
When should a nephrologist suspect a mitochondrial disease? Nefrologia (2015) 0.79
Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation (2013) 0.78
Obesity-related renal damage: changing diet to avoid progression. Kidney Int (2010) 0.78
The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti-β-2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation. Transplantation (2017) 0.77
Weight loss and proteinuria. Contrib Nephrol (2006) 0.76
Allergen-specific immunotherapy in horses with insect bite hypersensitivity: a double-blind, randomized, placebo-controlled study. Vet Dermatol (2013) 0.76
Risk factors for abnormal cervical cytology in pregnant women attending the high-risk obstetrics clinic at the University Hospital in San Juan, Puerto Rico. P R Health Sci J (2011) 0.76
[Persistent microhaematuria with negative or low proteinuria]. Nefrologia (2014) 0.76
On the feasibility of interoperable schemes in hand biometrics. Sensors (Basel) (2012) 0.75
[Purgative with high sodium phosphate contents: efficacious but not so safe]. Med Clin (Barc) (2006) 0.75
Reply to vascular endothelial growth factor: a novel potential therapeutic target for hypertension. J Clin Hypertens (Greenwich) (2013) 0.75
[Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study]. Nefrologia (2014) 0.75
Slowing the progression of renal failure. Kidney Int Suppl (2002) 0.75
Hepatitis C-induced renal disease in patients with AIDS: an emergent problem. Contrib Nephrol (2012) 0.75
Necrotizing Thrombophlebitis Secondary to Mycobacterium Chelonae in a Hemodialyzed Patient. Am J Dermatopathol (2017) 0.75
[Recessive dystrophic epidermolysis bullosa. Report of one case]. Rev Med Chil (2004) 0.75
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4. Am J Nephrol (2017) 0.75
Relapse of lupus nephritis more than 10 years after complete remission. Nephrol Dial Transplant (2005) 0.75
Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy. Clin Drug Investig (2007) 0.75
Two cases of glomerulonephritis in one patient infected with the hepatitis C virus. Nefrologia (2013) 0.75
Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. Nefrologia (2015) 0.75